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LATE ONSET NON-INFECTOUS PULMONARY COMPLICATIONS (LONIPC)
IN ADULT ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT (HCT) RE-
CIPIENTS
Solh, M., Cao, Q., Majhail, N.S., Weisdorf, D. University of Minnesota,
Minneapolis, MN
LONIPC after allogeneic HCT can contribute to post-transplant
morbidity and mortality and decreased quality of life. We reviewed
data for LONIPC in 451 consecutive adult patients who received
an allogeneic HCT between 2002 and 2007 and survived for $80
days after HCT. Seventy four patients developed LONIPC at a me-
dian of 177 (range, 81-1017) days after HCT; 1-year cumulative in-
cidence of LONIPC was 13% (95% CI, 10%-16%). LONIPC
occurred among 21.3% of myeloablative and 12.6% of non-myeloa-
blative HCT recipients. Graft sources were 49% related donor, 45%
umbilical cord blood and 51% unrelated donor. Acute GVHD had
occurred in 49%. 53% of patients had a prior history of or concom-
itant chronic GVHD. Four groups of LONIPC were observed: dif-
fuse alveolar hemorrhage (DAH, n5 28), idiopathic pneumonia
syndrome (IPS, n5 19), bronchiolitis obliterans (BO, n5 22) and
other (n5 5). A greater proportion of patients with LONIPChad re-
ceived myeloablative conditioning compared to patients who did not
develop LONIPC (57% vs 41%, p5 0.01); the two groups were oth-
erwise comparable. Overall survival at 1-year and 3-years after HCT
was significantly decreased for recipients with LONIPC compared
to those without LONIPC (1 year OS 51% vs. 76%, p\0.01) and
(3 yearsOS 34% vs 57%, p\0.01). 45%of recipients with LONIPC
survived 6 months after developing lung complication. Among pa-
tients with LONIPC, those with DAH and IPS had worse survival
at 1-year after HCT compared to patients with BO (36% vs. 37%
vs. 77%, p\0.01). LONIPC in allogeneic HCT recipients consists
of a heterogeneous group of diseases with varying clinical course and
prognosis. LONIPC is associated with increased mortality among
HCT receipients.Further understanding of the pathogenesis of
each of these entities is still required.184
NEPHROTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION: INCIDENCE AND OUTCOMES
Khaled, Y.A.2, Choi, S.W.1, Hanauer, D.A.3, Levine, J.E.1, Peres, E.1,
Kitko, C.1, Reddy, P.1 1University of Michigan, Ann Arbor, MI; 2Florida
Cancer Institute, Orlando, FL; 3University of Michigan, Ann Arbor, MI
The NIH Consensus recognizes nephrotic syndrome (NS) as part
of the chronic GVHD symptomatology, however the incidence and
outcomes of this manifestation have not been well-defined. To char-
acterize this complication, we conducted an IRB-approved retro-
spective review of 626 consecutive patients (age. 16 yrs: [MRD],
n5 352; [MUD], n5 274) who underwent allogeneic hematopoietic
cell transplantation (HCT) between October 2000 and December
2007 at theUniversity ofMichigan. Conditioning regimens included
full intensity (FIC) in 470 patients and reduced intensity (RIC) in 156
patients. Nephrotic range proteinuria was identified in 17 patients.
Renal biopsy confirmed the diagnosis in seven of these patients.
The median time to onset of NS was 7.3 months following HCT.
Clinical manifestations included hypoalbuminemia (100%), hyper-
cholesterolemia (82%), edema (76%), renal impairment (65%),
and thrombosis (29%). The overall cumulative incidence of NS
was 2.9%: 2.4% in FIC and 4.6% in RIC HCT recipients; and
2.3% inMRD and 3.7%MUDHCT recipients. Of note, in patients
who received irradiation-based conditioning regimens, there was an
increased cumulative incidence of NS compared to those who did
not, 4.8% versus 2.1%, respectively.
Diagnostic symptoms of chronic GVHD based upon the NIH
Consensus was seen in 11 patients (65%). Prior history of acute
GVHD was seen in 11 patients (65%). Interestingly, history of
symptomatic cystitis was seen in 9 patients (53%), eight of whom
had BK virus detected in the urine. All of the patients received sys-
temic steroids (0.25 mg/kg – 2 mg/kg), with or without mycopheno-late mofetil and a calcineurin inhibitor. Additional therapy with
rituximab was administered in nine patients. Durable remission
with no further recurrence of proteinuria was observed in 47% of
the patients (n5 8). The median time to response was 4.8 months.
Recurrence of proteinuria was seen in 29% of the patients (n5 5),
and primary refractory proteinuria was observed in 23% of the pa-
tients (n5 4). Overall survival for the cohort was 49.5% at 4 years
with median follow up of 5.1 years. The median survival from diag-
nosis ofNSwas 2.5 years. As ofMay 2009, eight patients are alive and
nine have died. The causes of death include GVHD (n5 6), relapse
(n5 2) and unknown (n5 1). NS is a rare but important complica-
tion following allogeneicHCT. Early recognition of the clinical pre-
sentations and risk factors may limit the potential morbidity and
mortality associated with NS.
Patients characteristic
ProteinuriaPatient
MUD/
MRD TAge at
ransplant DXestimate
(g/24 h) GenderGVHD
RegimenKidney
Biopsy1 MUD 53 MPD 5.5 F Tacro/MTX Minimal cange
GN2 MUD 56 MM 14 M Tacro/MTX Memberanous
GN3 MRD 57 MDS 14 M Tacro/MTX Memberanous
GN4 MUD 55 AML 3.4 M Tacro/MTX N/A5 MRD 30 NHL 3.74 M Tacro/MTX Memberanous
GN6 MRD 47 AML 10 M Tacro/MTX Memberanous
GN7 MUD 49 NHL 6.9 M Tacro/MMF N/A8 MUD 38 AML 8.7 F Tacro/MMF N/A9 MUD 18 Aplastic
Anemia4.22 F Tacro/MTX N/A10 MRD 34 AML 5.96 F Tacro/MTX N/A11 MUD 61 MDS 13.27 M Tacro/MTX N/A12 MRD 26 CMML 3.58 F Tacro/MMF N/A13 MRD 63 NHL 4.54 F Tacro/MMF/
MTXN/A14 MUD 55 AML 22.57 M Tacro/MTX/
Etanercept
Minimal Change
GN15 MRD 59 NHL 3.37 M Tacro/MMF N/A16 MRD 62 AML 5.47 F Tacro/MMF
/MTXMemberanous
GN17 MUD 46 AML 7.96 F Tacro/MTX/
EtanerceptN/AMUD5matched unrelated donor; MRD5matched related donor;
GN5 glomerulonephritis; NA5 non applicable; MTX5methotrex-
ate; MMF5mycophenolate mofrtil;185
UTILIZATION OF PREVENTIVE CARE SERVICES BY HEMATOPOIETIC CELL
TRANSPLANT SURVIVORS
Lee, S.J., Leisenring, W.M., Khera, N., Chow, E.J., Syrjala, K.L.,
Baker, K.S., Flowers, M.E.D., Martin, P.J. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background andMethods: Screening and preventive care guidelines
are available for survivors of autologous and allogeneic hematopoietic
cell transplantation (HCT).We assessed adherence to these guidelines
with a mailed questionnaire sent to all adult survivors in the Fred
Hutchinson Cancer Research Center database, and examined factors
associated with adherence.
Results:Of 3780 survivors after HCT, 1849 (49%) responded. Me-
dian age of respondents at the time of the survey was 55.3 years (18.2-
81.2). 53% were male, 90% White, 68% allogeneic recipients, and
the median time elapsed since transplant was 8.1 years (0.2-38.1).
Younger age, male gender, non-White race, bone marrow trans-
plant, myeloablative conditioning, allogeneic HCT, and HCT in
